The FDA issued a complete response letter for SYD-101, citing insufficient evidence of effectiveness despite achieving ...

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

Sydnexis, Inc., ( a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL ...

The FDA declined to approve SYD-101, a low-dose atropine formulation that would have been the first pharmaceutical treatment ...

Developed by Paris, France-based EssilorLuxottica and made for children as young as 6, the brand-new Stellest lenses slow the ...

Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...

It’s common to have changes in your vision as you age, and the risk of developing eye disease unfortunately also increases as ...

Age-related macular degeneration is a common cause of vision loss, with existing treatments only able to slow its progression ...

An electronic retinal implant has improved vision in people with age-related macular degeneration—but it isn’t a full ...

Geographic atrophy due to age-related macular degeneration (AMD) is the leading cause of irreversible blindness and affects more than 5 million persons worldwide. No therapies to restore vision in ...

UC Irvine researchers have discovered that supplementing the eye with special fatty acids can reverse vision loss caused by aging—at least in mice.